Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alumis Inc (ALMS)

Alumis Inc (ALMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,675,592
  • Shares Outstanding, K 104,393
  • Annual Sales, $ 0 K
  • Annual Income, $ -294,230 K
  • EBIT $ -456 M
  • EBITDA $ -453 M
  • 60-Month Beta -2.06
  • Price/Sales 83.95
  • Price/Cash Flow N/A
  • Price/Book 7.21

Options Overview Details

View History
  • Implied Volatility 109.69% (+16.38%)
  • Historical Volatility 205.10%
  • IV Percentile 29%
  • IV Rank 4.18%
  • IV High 1,143.00% on 11/12/25
  • IV Low 64.56% on 08/27/25
  • Expected Move (DTE 8) 2.42 (9.04%)
  • Put/Call Vol Ratio 0.40
  • Today's Volume 342
  • Volume Avg (30-Day) 903
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 14,686
  • Open Int (30-Day) 15,589
  • Expected Range 24.38 to 29.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.90
  • Number of Estimates 4
  • High Estimate -0.79
  • Low Estimate -1.04
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.20 +32.67%
on 01/13/26
28.29 -5.27%
on 01/29/26
+5.71 (+27.07%)
since 01/12/26
3-Month
4.60 +482.61%
on 11/14/25
28.29 -5.27%
on 01/29/26
+21.56 (+411.45%)
since 11/12/25
52-Week
2.76 +870.98%
on 06/24/25
28.29 -5.27%
on 01/29/26
+21.77 (+432.80%)
since 02/12/25

Most Recent Stories

More News
Alumis to Participate in Upcoming February Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 26.80 (+4.56%)
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 26.80 (+4.56%)
Alumis Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 26.80 (+4.56%)
Should You Chase the Rally in Alumis Stock Today?

Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s how you should play ALMS shares in 2026.

JNJ : 244.55 (+1.53%)
ALMS : 26.80 (+4.56%)
BMY : 59.86 (-0.12%)
Alumis Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 26.80 (+4.56%)
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

– Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis – – Approximately 65% of patients achieved...

ALMS : 26.80 (+4.56%)
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

– Conference Call and Webcast to be held Tuesday, January 6, 2026, at 8:00 a.m. ET – SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma...

ALMS : 26.80 (+4.56%)
Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 26.80 (+4.56%)
Alumis to Participate in Upcoming November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 26.80 (+4.56%)
Alumis to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 26.80 (+4.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alumis Inc. is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. The company's product candidate includes ESK-001. Alumis Inc. is based in SOUTH SAN...

See More

Key Turning Points

3rd Resistance Point 31.12
2nd Resistance Point 29.45
1st Resistance Point 28.13
Last Price 26.80
1st Support Level 25.14
2nd Support Level 23.47
3rd Support Level 22.15

See More

52-Week High 28.29
Last Price 26.80
Fibonacci 61.8% 18.54
Fibonacci 50% 15.53
Fibonacci 38.2% 12.51
52-Week Low 2.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar